CompletedNCT02324725
Biological Markers During Extended-Release Naltrexone Treatment for Opioid Use
About this title
Read the official source — NCT02324725Medication studyAges 18–55United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- PhiladelphiaSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: October 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 32
- Sponsor
- University of Pennsylvania
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT02324725
- Official title
Show the full official title
Biomarkers of Disease and Response to Treatment in Opioid Addiction
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Philadelphia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is University of Pennsylvania, a university.
Did this study involve medication?
Yes. The study involved medication, including Naltrexone.
Who was this study for?
Listed age limits: 18 years to 55 years.
